Waldenstrom Macroglobulinemia clinical trials at UC Health
6 in progress, 4 open to eligible people
A Phase 1 Dose-Escalation and Cohort-Expansion of VLS-101 in Hematologic Malignancies
open to eligible people ages 18 years and up
This is a Phase 1 study evaluating the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of VLS-101, an antibody-drug conjugate (ADC) that targets receptor tyrosine kinase-like orphan receptor 1 (ROR1) on cancer cells. The study is evaluating VLS-101 in patients with previously treated hematological cancers.
at UCLA UCSD
A Study of ARQ 531 in Patients With Selected Hematologic Malignancies
open to eligible people ages 18 years and up
This is an open-label, multi-center Phase 1/2 study of ARQ 531 in patients with selected hematologic malignancies.
at UCLA
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL
open to eligible people ages 18 years and up
This is an open-label, multi-center Phase 1/2 study of oral LOXO-305 in patients with CLL/SLL and NHL who have failed or are intolerant to standard of care.
at UCSF
Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers
open to eligible people ages 18 years and up
This is an open-label Phase 1b/2 study in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)or non hodgkin's lymphoma (NHL) who have failed prior standard of care therapies including a BTK inhibitor where one is approved for the indication.
at UC Irvine UCSD
A Long-term Extension Study of PCI-32765 (Ibrutinib)
Sorry, accepting new patients by invitation only
The purpose of this study is to collect long-term safety and efficacy data for participants treated with PCI-32765 (Ibrutinib) and to provide ongoing access to PCI-32765 for participants who are currently enrolled in PCI-32765 studies that have been completed according to the parent protocol, are actively receiving treatment with PCI-32765, and who continue to benefit from PCI-32765 treatment.
at UCLA UCSD
A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM)
Sorry, in progress, not accepting new patients
This study is to evaluate the safety, efficacy and clinical benefit of BGB-3111 (Zanubrutinib) vs ibrutinib in participants with MYD88 Mutation Waldenström's Macroglobulinemia.
at UCSD
Last updated: